Publications & Presentations
February 20, 2020
The past year saw a number of important developments affecting the 340B Drug Discount Program. With lawmakers and regulators continuing to focus on drug prices and price transparency, it is highly likely that 2020 will be a critical year for the 340B program.
This article (authored by Polsinelli Health Care and Public Policy professionals) provides an in-depth review of the latest developments impacting the 340B program and offers predictions for 2020. All 340B stakeholders should continue to monitor 340B program developments and provide input through the rulemaking comment process and otherwise.
View the full article here.